| REVIEW ARTICLE |
|
| Year : 2022 | Volume
: 40
| Issue : 2 | Page : 67-70 |
|
|
Recommendations on use of systemic treatments for immune-mediated dermatologic disorders in patients with confirmed COVID-19 infection: A rapid review
Chia-Ling Yu1, Yu-Ting Lin1, Ching-Chi Chi2
1 Department of Pharmacy, Chang Gung Memorial Hospital, Linkou, Taoyuan, Taiwan
2 Department of Dermatology, Chang Gung Memorial Hospital, Linkou; School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan
Correspondence Address:
Prof. Ching-Chi Chi
Department of Dermatology, Chang Gung Memorial Hospital, Linkou, 5, Fuxing Street, Guishan District, Taoyuan
Taiwan
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/1027-8117.349030
|
|
|
With the rapid outbreak of the coronavirus disease 2019 (COVID-19) pandemic, considerable concerns about the safety of systemic treatments of immune-mediated dermatologic disorders has been raised by dermatologists and their patients. We aimed to perform a rapid review of latest American and European guidelines on the use of systemic treatments in patients with immune-mediated dermatologic disorders and confirmed COVID-19 infection and to provide recommendations to inform practice. Based on the current limited guidelines and evidence, systemic corticosteroids should not be abruptly discontinued and the lowest effective dose should be continued. Systemic immunosuppressants (including methotrexate, cyclosporine, azathioprine, cyclophosphamide, and leflunomide), biologics, and sulfasalazine should be withheld in patients with confirmed COVID-19 infection. Whether to continue Janus kinase inhibitors should be determined following a shared decision-making process between dermatologists and patients after considering patients' medical conditions and risk for severe COVID.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
